The Cancer Biology Training Program (the Program) at The University of Michigan, currently in its twentieth year, is an interdisciplinary program whose central goal is to train exceptional junior investigators to address fundamental biological problems related to human cancer. The Program draws its strength from: the participation of 40 faculty members from 14 basic science and clinical departments within The University of Michigan;its association with The University of Michigan Comprehensive Cancer Center;and its involvement with the Program in Biomedical Sciences, through which graduate students are recruited to the Program. The Program trains both predoctoral and postdoctoral scholars with research opportunities focusing on a wide choice of topics in the field of cancer biology. In addition, it provides these trainees with didactic coursework and other programmatic activities that expose them to the depth and breadth of cancer research. Postdoctoral fellows will have completed a Ph.D. degree in one of the physical or biological sciences, or have completed an M.D. degree. Predoctoral students will comprise a subset of students accepted into the recently-approved Doctoral Program in Cancer Biology. All trainees have a significant interest in pursuing a career in some aspect of cancer-related research. Predoctoral trainees will be expected to graduate to outstanding postdoctoral positions, while postdoctoral trainees should assume leading academic and research positions.

Public Health Relevance

Cancer is one of the leading causes of illness and death in the United States. Determining the causes of cancer and discovery of new therapeutic approaches is required to improve the outcomes of cancer patients. The purpose of this grant is to train the next generation of cancer researchers, allowing them to make strides in the future as we continue to battle this disease.

National Institute of Health (NIH)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Ojesina, Akinyemi I; Lichtenstein, Lee; Freeman, Samuel S et al. (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506:371-5
Mineharu, Yohei; Kamran, Neha; Lowenstein, Pedro R et al. (2014) Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther 13:3024-36
Walczak, Elisabeth M; Kuick, Rork; Finco, Isabella et al. (2014) Wnt signaling inhibits adrenal steroidogenesis by cell-autonomous and non-cell-autonomous mechanisms. Mol Endocrinol 28:1471-86
Jones, Morgan; Osawa, Gail; Regal, Joshua A et al. (2014) Hematopoietic stem cells are acutely sensitive to Acd shelterin gene inactivation. J Clin Invest 124:353-66
Lowenstein, P R; Yadav, Viveka Nand; Chockley, Peter et al. (2014) There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther 22:246-7
Vainshtein, Jeffrey M; Spector, Matthew E; McHugh, Jonathan B et al. (2014) Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:513-9
VanderVeen, Nathan; Paran, Christopher; Appelhans, Ashley et al. (2014) Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev 1:
Prensner, John R; Chen, Wei; Iyer, Matthew K et al. (2014) PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74:1651-60
Assi, Hikmat H; Paran, Chris; VanderVeen, Nathan et al. (2014) Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther 349:458-69
Baker, Gregory J; Chockley, Peter; Yadav, Viveka Nand et al. (2014) Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res 74:5079-90

Showing the most recent 10 out of 86 publications